Professor Mehrdad Shamloo has held several positions at various biopharmaceutical companies in the San Francisco Bay Area, with demonstrated extensive focus on both CNS drug discovery and pre-clinical development. In 2008, Dr. Shamloo joined Stanford University and established the Behavioral and Functional Neuroscience Core Laboratory (BFNL), as well as his own research laboratory which focused on the furtherment of understanding of normal and pathological brain functions in neurological disorders such as Alzheimer’s disease (AD), Parkinson’s disease (PD), stroke and autism.

Dr. Shamloo’s efforts and research are currently directed towards the neurodegenerative pathways responsible for Selective Neuronal Vulnerability of sensitive brain nuclei in the aforementioned disorders. Through these investigations, his aim is to understand the processes leading to the functional and behavioral malfunction in these neurological disorders, and to subsequently develop novel therapeutics to treat them. Long term, Dr. Shamloo seeks to accelerate the translation of experimental discoveries to novel therapeutic approaches, and to ultimately improve the quality of life for patients with brain disorders.